- Home
- PCM vs SRPT Comparison
PCM vs SRPT Comparison
Compare PCM & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCM
- SRPT
- Stock Information
- Founded
- PCM 1993
- SRPT 1980
- Country
- PCM United States
- SRPT United States
- Employees
- PCM N/A
- SRPT N/A
- Industry
- PCM Trusts Except Educational Religious and Charitable
- SRPT Biotechnology: Pharmaceutical Preparations
- Sector
- PCM Finance
- SRPT Health Care
- Exchange
- PCM Nasdaq
- SRPT Nasdaq
- Market Cap
- PCM 77.7M
- SRPT 1.7B
- IPO Year
- PCM N/A
- SRPT 1997
- Fundamental
- Price
- PCM $6.34
- SRPT $18.38
- Analyst Decision
- PCM
- SRPT Buy
- Analyst Count
- PCM 0
- SRPT 25
- Target Price
- PCM N/A
- SRPT $61.57
- AVG Volume (30 Days)
- PCM 29.1K
- SRPT 6.0M
- Earning Date
- PCM 01-01-0001
- SRPT 08-06-2025
- Dividend Yield
- PCM 11.68%
- SRPT N/A
- EPS Growth
- PCM N/A
- SRPT N/A
- EPS
- PCM N/A
- SRPT N/A
- Revenue
- PCM N/A
- SRPT $2,233,371,000.00
- Revenue This Year
- PCM N/A
- SRPT $19.93
- Revenue Next Year
- PCM N/A
- SRPT N/A
- P/E Ratio
- PCM N/A
- SRPT N/A
- Revenue Growth
- PCM N/A
- SRPT 59.15
- 52 Week Low
- PCM $6.88
- SRPT $16.88
- 52 Week High
- PCM $10.20
- SRPT $153.30
- Technical
- Relative Strength Index (RSI)
- PCM 49.99
- SRPT 31.79
- Support Level
- PCM $6.28
- SRPT $17.95
- Resistance Level
- PCM $6.49
- SRPT $19.79
- Average True Range (ATR)
- PCM 0.06
- SRPT 1.06
- MACD
- PCM -0.00
- SRPT 0.96
- Stochastic Oscillator
- PCM 34.78
- SRPT 51.55
About PCM PCM Fund Inc.
Pcm Fund Inc is a closed-end investment management company. Its investment objective is to seek current income as a primary focus and also capital appreciation. The Fund invests in agency-guaranteed mortgage-backed securities, private-label mortgage-backed securities, high-yield corporate debt securities, and commercial mortgage-backed securities.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.